FindTrial
Sign In

Menjugate™

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaDiphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria MeniHaemophilus Influenzae Type bHepatitis BNeisseria MeningitidisPoliomyelitisTetanus

Phase 2

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
CompletedNCT00871338
GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis
Start: 2009-06-24End: 2010-12-09Updated: 2018-06-06
Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants
CompletedNCT01098474
GlaxoSmithKlineTuberculosis
Start: 2010-07-07End: 2012-03-16Updated: 2019-06-27
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose
CompletedNCT01171989
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni +4
Start: 2010-08-18End: 2010-12-03Updated: 2020-01-21

Related Papers

Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.
2014-08-0942 citations
A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
2013-07-016 citations